Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
PAVmed Inc is a medical device company engaged in advancing a pipeline of medical technologies from concept to commercialization using a business model focused on capital and time efficiency. Its product includes EsoCheck; CarpX; EsoGuard; PortIO; DisappEAR and others. PAVmed Inc is a medical device company engaged in advancing a pipeline of medical technologies from concept to commercialization using a business model focused on capital and time efficiency. Its product includes EsoCheck; CarpX; EsoGuard; PortIO; DisappEAR and others.
Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test PR Newswire NEW YORK, Nov. 20, 2024 NEW YORK, Nov. 20, 2024 /PRNewswire/...
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum PR Newswire NEW YORK, Nov. 18, 2024 NEW YORK, Nov. 18, 2024 /PRNewswire/...
PAVmed Provides Business Update and Third Quarter 2024 Financial Results PR Newswire NEW YORK, Nov. 14, 2024 Lucid reports record quarterly EsoGuard® revenue and completes clinical evidence...
Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication PR Newswire NEW YORK, Nov. 7...
Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers PR Newswire NEW YORK, Nov. 5, 2024 Industry veterans from leading cancer...
PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024 PR Newswire NEW YORK, Oct. 31, 2024 Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, Oct. 31, 2024...
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 13, 2024 PR Newswire NEW YORK, Oct. 30, 2024 Conference Call and Webcast at 8:30AM Eastern Time NEW YORK, Oct...
Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test PR Newswire NEW YORK, Oct. 15, 2024 Patent covers proprietary method using methylation of...
PAVmed Subsidiary, Veris Health, Awarded $1.8 Million NIH Grant to Enhance Cancer Care PR Newswire NEW YORK, Oct. 10, 2024 Grant will fund research to optimize Veris Cancer Care Platform for...
Lucid Diagnostics to Participate in the 2024 Maxim Healthcare Virtual Summit PR Newswire NEW YORK, Oct. 9, 2024 NEW YORK, Oct. 9, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq:...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.01 | -0.980392156863 | 1.02 | 1.17 | 0.99 | 114041 | 1.07252371 | CS |
| 4 | -0.04 | -3.80952380952 | 1.05 | 1.21 | 0.99 | 53043 | 1.07305179 | CS |
| 12 | 0.11 | 12.2222222222 | 0.9 | 1.9 | 0.8 | 65291 | 1.27124788 | CS |
| 26 | -0.79 | -43.8888888889 | 1.8 | 1.96 | 0.5999 | 65003 | 1.12095707 | CS |
| 52 | -2.155 | -68.0884676145 | 3.165 | 4.875 | 0.5999 | 101376 | 2.61428569 | CS |
| 156 | -63.19 | -98.4267912773 | 64.2 | 64.425 | 0.5999 | 683621 | 18.95215192 | CS |
| 260 | -13.54 | -93.058419244 | 14.55 | 145.5 | 0.5999 | 1164530 | 47.52156657 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Premium
